Antiretroviral  	Antiretroviral  	 JJ	B-NP
drug  	drug  	 NN	I-NP
development  	development  	 NN	I-NP
for  	for  	 IN	I-NP
HIV 	HIV 	 NNP	I-NP
:  	:  	 :	O
challenges  	challenges  	 NNS	O
for  	for  	 IN	O
the  	the  	 DT	O
future  	future  	 NN	O
The  	The  	 DT	O
scarcity  	scarcity  	 NN	O
of  	of  	 IN	O
new  	new  	 JJ	O
innovative  	innovative  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
development  	development  	 NN	B-NP
pipeline  	pipeline  	 NN	I-NP
for  	for  	 IN	O
combating  	combating  	 VBG	O
HIV  	HIV  	 NNP	B-NP
replication  	replication  	 NN	O
may  	may  	 MD	O
signal  	signal  	 VB	O
a  	a  	 DT	O
change  	change  	 NN	O
in  	in  	 IN	O
direction  	direction  	 NN	O
for  	for  	 IN	O
HIV  	HIV  	 NNP	B-NP
researchers  	researchers  	 NNS	O
and  	and  	 CC	O
drug  	drug  	 NN	B-NP
developers 	developers 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
of  	of  	 IN	O
introducing  	introducing  	 VBG	B-NP
drugs  	drugs  	 NNS	I-NP
with  	with  	 IN	O
incremental  	incremental  	 JJ	B-NP
improvements  	improvements  	 NNS	I-NP
within  	within  	 IN	O
existing  	existing  	 VBG	B-NP
drug  	drug  	 NN	I-NP
classes  	classes  	 NNS	I-NP
is  	is  	 VBZ	O
no  	no  	 RB	O
longer  	longer  	 RBR	O
commercially  	commercially  	 RB	O
viable 	viable 	 JJ	O
.  	.  	 .	O
While  	While  	 IN	O
an  	an  	 DT	O
argument  	argument  	 NN	O
can  	can  	 MD	O
be  	be  	 VB	O
made  	made  	 VBN	O
that  	that  	 IN	O
drugs  	drugs  	 NNS	O
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
novel  	novel  	 NN	O
targets  	targets  	 NNS	O
may  	may  	 MD	O
have  	have  	 VB	O
a  	a  	 DT	O
greater  	greater  	 JJR	O
impact 	impact 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
list  	list  	 NN	O
of  	of  	 IN	O
such  	such  	 JJ	O
targets  	targets  	 NNS	O
is  	is  	 VBZ	O
limited  	limited  	 VBN	O
and  	and  	 CC	O
the  	the  	 DT	O
scientific  	scientific  	 JJ	B-NP
challenge  	challenge  	 NN	I-NP
of  	of  	 IN	O
intervening  	intervening  	 VBG	O
at  	at  	 IN	O
another  	another  	 DT	O
stage  	stage  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
HIV  	HIV  	 NNP	B-NP
replication  	replication  	 JJ	O
cycle  	cycle  	 NN	O
is  	is  	 VBZ	O
high 	high 	 JJ	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
envision  	envision  	 VB	O
a  	a  	 DT	O
realistic  	realistic  	 JJ	O
risk 	risk 	 NN	B-NP
/ 	/ 	 CD	I-NP
reward  	reward  	 NN	I-NP
scenario  	scenario  	 NN	I-NP
that  	that  	 WDT	O
will  	will  	 MD	O
ensure  	ensure  	 VB	O
continued  	continued  	 JJ	O
investment  	investment  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
discovery  	discovery  	 NN	O
of  	of  	 IN	O
novel  	novel  	 NN	O
HIV  	HIV  	 NN	B-NP
drugs  	drugs  	 NNS	O
that  	that  	 WDT	O
simply  	simply  	 RB	O
block  	block  	 VB	O
replication  	replication  	 NNS	B-NP
and  	and  	 CC	O
suppress  	suppress  	 JJ	O
plasma  	plasma  	 JJ	B-NP
viral  	viral  	 JJ	I-NP
load 	load 	 NN	I-NP
.  	.  	 .	O
Recently 	Recently 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
scientific  	scientific  	 JJ	B-NP
community  	community  	 NN	I-NP
should  	should  	 MD	O
move  	move  	 VB	O
research  	research  	 NN	O
in  	in  	 IN	O
a  	a  	 DT	O
new  	new  	 JJ	O
direction 	direction 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
goal  	goal  	 NN	O
of  	of  	 IN	O
attacking  	attacking  	 VBG	O
the  	the  	 DT	O
reservoirs  	reservoirs  	 NN	O
of  	of  	 IN	O
latent  	latent  	 JJ	O
HIV  	HIV  	 NN	B-NP
that  	that  	 WDT	O
persist  	persist  	 VBP	O
despite  	despite  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
current  	current  	 JJ	O
drugs  	drugs  	 NNS	O
to  	to  	 TO	O
achieve  	achieve  	 VB	O
a  	a  	 DT	O
functional  	functional  	 JJ	B-NP
cure 	cure 	 NN	I-NP
,  	,  	 ,	O
if  	if  	 IN	O
not  	not  	 RB	O
a  	a  	 DT	O
sterilizing  	sterilizing  	 JJ	O
cure 	cure 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
process  	process  	 NN	O
will  	will  	 MD	O
have  	have  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
a  	a  	 DT	O
long-term  	long-term  	 JJ	O
commitment 	commitment 	 NN	O
,  	,  	 ,	O
primarily  	primarily  	 RB	O
funded  	funded  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
NIH 	NIH 	 NNP	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
some  	some  	 DT	O
involvement  	involvement  	 NN	O
by  	by  	 IN	O
the  	the  	 DT	O
pharmaceutical  	pharmaceutical  	 JJ	O
and  	and  	 CC	O
biotechnology  	biotechnology  	 NN	O
industries 	industries 	 NNS	O
.  	.  	 .	O
While  	While  	 IN	O
most  	most  	 JJS	O
individuals  	individuals  	 NNS	O
infected  	infected  	 VBN	O
with  	with  	 IN	O
HIV  	HIV  	 NNP	B-NP
can  	can  	 MD	O
achieve  	achieve  	 VB	O
viral  	viral  	 JJ	B-NP
suppression  	suppression  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
approved  	approved  	 JJ	O
therapies 	therapies 	 NNS	O
,  	,  	 ,	O
treatment  	treatment  	 NN	O
is  	is  	 VBZ	O
lifelong 	lifelong 	 JJ	O
,  	,  	 ,	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
are  	are  	 VBP	O
significant  	significant  	 JJ	O
and  	and  	 CC	O
resistance  	resistance  	 NN	O
will  	will  	 MD	O
eventually  	eventually  	 RB	O
render  	render  	 VB	O
more  	more  	 JJR	O
of  	of  	 IN	O
these  	these  	 DT	O
drugs  	drugs  	 NNS	O
less  	less  	 RBR	O
effective 	effective 	 JJ	O
.  	.  	 .	O
New  	New  	 NNP	O
and  	and  	 CC	O
innovative  	innovative  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
must  	must  	 MD	O
be  	be  	 VB	O
developed  	developed  	 VBN	O
to  	to  	 TO	O
prevent  	prevent  	 VB	O
viral  	viral  	 JJ	B-NP
infection  	infection  	 NN	I-NP
and  	and  	 CC	O
further  	further  	 RB	O
improve  	improve  	 VB	O
the  	the  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	O
for  	for  	 IN	O
those  	those  	 DT	O
individuals  	individuals  	 NNS	O
who  	who  	 WP	O
are  	are  	 VBP	O
already  	already  	 RB	O
infected 	infected 	 VBN	O
.  	.  	 .	O
